Capricor Therapeutics (NASDAQ:CAPR) Announces Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Posted by Francis Steltz on May 12th, 2026

Capricor Therapeutics (NASDAQ:CAPR – Get Free Report) announced its quarterly earnings results on Tuesday. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04), FiscalAI reports.

Capricor Therapeutics Stock Performance

Capricor Therapeutics stock traded down $0.38 during trading hours on Tuesday, reaching $31.52. 1,054,237 shares of the stock were exchanged, compared to its average volume of 1,285,162. Capricor Therapeutics has a 52-week low of $4.30 and a 52-week high of $40.37. The stock has a market cap of $1.82 billion, a P/E ratio of -13.95 and a beta of 0.48. The firm’s 50 day moving average is $31.57 and its 200 day moving average is $23.69.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on CAPR shares. Cantor Fitzgerald set a $62.00 price objective on Capricor Therapeutics and gave the stock an “overweight” rating in a report on Friday, March 13th. Piper Sandler reissued an “overweight” rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Capricor Therapeutics in a research note on Tuesday, March 10th. Finally, B. Riley Financial lifted their price target on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research report on Friday, March 13th. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.09.

Check Out Our Latest Analysis on Capricor Therapeutics

Insider Activity

In other news, Director Karimah Es Sabar sold 7,529 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $32.00, for a total transaction of $240,928.00. Following the transaction, the director directly owned 7,529 shares in the company, valued at $240,928. The trade was a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Anthony Bergmann sold 25,000 shares of the stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $31.70, for a total transaction of $792,500.00. Following the transaction, the chief financial officer directly owned 8,223 shares of the company’s stock, valued at $260,669.10. This represents a 75.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 172,529 shares of company stock worth $5,302,440. Insiders own 9.20% of the company’s stock.

Institutional Trading of Capricor Therapeutics

A number of institutional investors have recently modified their holdings of the business. Suvretta Capital Management LLC purchased a new position in Capricor Therapeutics in the fourth quarter worth $51,533,000. Tang Capital Management LLC purchased a new position in shares of Capricor Therapeutics in the 4th quarter valued at about $49,062,000. RA Capital Management L.P. acquired a new stake in shares of Capricor Therapeutics in the fourth quarter valued at about $43,516,000. Geode Capital Management LLC boosted its holdings in Capricor Therapeutics by 5.8% during the fourth quarter. Geode Capital Management LLC now owns 1,017,332 shares of the biotechnology company’s stock worth $29,367,000 after buying an additional 55,766 shares in the last quarter. Finally, State Street Corp boosted its holdings in Capricor Therapeutics by 3.5% during the fourth quarter. State Street Corp now owns 829,521 shares of the biotechnology company’s stock worth $23,940,000 after buying an additional 28,177 shares in the last quarter. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

(Get Free Report)

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.